Lantheus has three shots on goal to challenge Novartis

This week’s tie-up with Point Biopharma sets Lantheus up to compete directly against Novartis, potentially challenging the Swiss group’s recently launched radioligand-based therapeutics Pluvicto, targeting PSMA, and Lutathera, an anti-SSTR.